The need for new cancer medicines remains enormous. Because of this, we remain committed to building on our existing legacy in cancer treatment and re-establishing ourselves as a leader in this urgent area of patient care.
Sanofi’s work in oncology dates back decades and has focused on a number of cancer types including colon, colorectal and prostate cancers, in addition to products used in kidney transplantation.
We are expanding our contributions in the treatment of cancer by building a pipeline of future therapies in immuno-oncology, in which a patient’s own immune system is used to fight cancer cells.
Our first immuno-oncology therapy, developed in collaboration with Regeneron, has been approved in the U.S. for patients as the only treatment for patients with advanced cutaneous squamous cell carcinoma (CSCC), the deadliest non-melanoma skin cancer.
Through rigorous research and development efforts, we are continuing to rapidly advance our oncology pipeline. We are studying oncology and immuno-oncology therapies to address medical needs in a variety of other areas including multiple myeloma, basal cell carcinoma, cervical cancer, lung cancer, breast cancer (triple negative and estrogen-receptor positive), colon cancer, gastric cancer, prostate cancer and Hodgkin’s lymphoma.
Inspired by patients around the world
Above from left to right: Darryl, prostate cancer, USA; James, prostate cancer, USA; John, prostate cancer, USA